Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL-5 topical spray for superficial mild to moderate secondary wound infection
CTR20231275Phase 3Completed
- Sponsor
- Changchun Pulike Biological Pharmaceutical
- Start
- Apr 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of peceleganan in Wound infection (WI), sponsored by Changchun Pulike Biological Pharmaceutical. Started Apr 2023; status: completed.
02
Drugs
peceleganan
03
Conditions
Wound infection (WI)
Beyond the preview
Go deeper on CTR20231275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231275.